Fishers startup prepares to go public
Four-year-old Novusterra Inc. is planning an initial public offering within 90 days and hopes to be approved to trade on the OTCQB Venture Market, often used by companies that are still developing.
Four-year-old Novusterra Inc. is planning an initial public offering within 90 days and hopes to be approved to trade on the OTCQB Venture Market, often used by companies that are still developing.
The university plans to launch degree programs in occupational therapy, physical therapy and other rehabilitative health care services, and expand undergraduate and graduate nursing programs, with additional locations.
The Richard M. Fairbanks Foundation said the grants are part of a $14 million initiative to reverse declining college enrollment.
Lilly said its new option will help millions of adults with obesity access the medicine they need, including those not eligible for the Zepbound savings card program, those without employer coverage, and those who need to self-pay outside of insurance.
The five-year-old, clinical-stage drugmaker has already raised more than $213 million to develop therapeutics to treat rare endocrine disorders, a huge amount for a startup.
If all goes to schedule, the huge power plant about 125 miles southwest of Indianapolis will convert to natural gas and burn its last load of coal by the end of 2026.
Lilly is moving about 200 scientists and researchers who had worked in nearby Cambridge, Massachusetts, to the new center, and plans to add about 300 employees.
The Indianapolis-based philanthropic foundation said Thursday that more than 80 public, private and charter school districts and networks representing more than 300 schools in Marion County are eligible to apply for grants.
Last month, the federal Medicare program proposed a 2.9% cut to physician pay for 2025. That marked the fifth straight year that regulators proposed cutting payments to doctors for thousands of services, from stitching a wound to replacing a knee.
The investment would make AES Indiana the first utility in Indiana to abandon the use of coal as a fuel source, if state regulators agree, the company said.
Davis has dedicated 37 years of his career to Indiana Landmarks, the nation’s largest statewide preservation organization, which has helped preserve scores of historic buildings across the state.
The Indianapolis-based drugmaker said revenue increased 36% in the quarter, to $11.3 billion. Zepbound, the popular obesity drug that launched in December, crossed into blockbuster territory, with sales of $1.23 billion in the quarter.
MBX is focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, such as hypoparathyroidism, post-bariatric hypoglycemia and obesity.
The five-year implementation grants range from $12.1 million to $32 million each, with DePauw University in Greencastle landing the largest grant.
Indiana University Health, one of the state’s largest hospital systems, saw patient volumes and revenue grow in the first six months of the year, but saw operating income fall as the costs of labor, supplies and drugs increased to meet higher demand for surgeries and patient care.
The program aims to reduce the likelihood of future violence by engaging victims of gun violence and their families with long-term services and support.
The expansion projects in three central Indiana communities are part of a larger investment the company said it is making across the Midwest to senior living and assisted living services in Indiana, Kentucky, Michigan and Ohio.
The spotlight is turning to Indianapolis-based Eli Lilly and Co. as the next possible member of the so-called “Trillion-Dollar Club,” based on the drugmaker’s climbing stock price and swelling demand for its treatments for diabetes, obesity and other diseases.
Despite the decrease, Community Health Network saw an increase in admissions, emergency visits, deliveries and physician outpatient visits during the first six months of 2024.
It was a mating dance that lasted more than three years. At the end, Eli Lilly and Co. wound up buying a Massachusetts-based biotech developing treatments for inflammatory bowel disease for $3.2 billion.